Nivolumab-based ELISA revealed increased serum PD-1 levels in advanced RCC patients

Mizutani, K; Horie, K; Kato, T; Nakane, K; Kawakami, K; Fujita, Y; Ito, M

CANCER RESEARCH, 2019; 79 (13):